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Abstract
Adverse drug events (ADE) are prevalent and costly. Clinical trials are constrained in their ability to identify potential
ADEs, motivating the development of spontaneous reporting systems for post-market surveillance. Statistical methods
provide a convenient way to detect signals from these reports but have limitations in leveraging relationships be-
tween drugs and ADEs given their discrete count-based nature. A previously proposed method, aer2vec, generates
distributed vector representations of ADE report entities that capture patterns of similarity but cannot utilize lexical
knowledge. We address this limitation by retrofitting aer2vec drug embeddings to knowledge from RxNorm and
developing a novel retrofitting variant using vector rescaling to preserve magnitude. When evaluated in the context
of a pharmacovigilance signal detection task, aer2vec with retrofitting consistently outperforms dispropor-
tionality metrics when trained on minimally preprocessed data. Retrofitting with rescaling results in further
improvements in the larger and more challenging of two pharmacovigilance reference sets used for evaluation.
Introduction
Adverse events (AE) were first defined as “injuries caused by medical management, and of the subgroup of such
injuries that resulted from negligent or substandard care”1. As a subgroup of AE, adverse drug events (ADE) are thus
defined as injuries due to medication. ADEs are common, costly, and sometimes preventable. Kaushal et al reported an
ADE rate of 10% (10 potential ADEs per 100 admissions) in two pediatric care clinics2. A report entitled Preventing
Medication Errors, by the Institute of Medicine, estimated a cost of $1,983 per preventable ADE, with national annual
cost of $887 million, while claiming that at least a quarter of all ADEs are preventable3. A challenge for prevention is
that many adverse effects of drugs are not known before their release to market, in part because clinical trials are not
sufficiently large or inclusive to account for the variety of human responses to a given pharmaceutical agent4.
To address this issue, the World Health Organization (WHO) established the WHO Global Monitoring Programme in
1968, with 10 pilot countries. However, the international community did not recognize the importance of sharing ADE
information until 1982 when benoxaprofen was reported to cause 12 deaths in the two years after its initial release
in the US5. Subsequently, the community made changes to adopt better epidemiological techniques and information
systems to share information. With national and international organizations, such as the United States Food and
Drug Administration (FDA), the WHO and the European Medicines Agency (EMA), countries are developing their
own reporting system infrastructures. The spontaneous reporting system in the U.S. is managed by the FDA, with
voluntary adverse drug reaction case reports sent directly to the FDA or drug manufacturers by healthcare professionals
and consumers, and retained in the FDA Adverse Event Reporting System (FAERS) database.
In order to detect ADEs from FAERS data, several statistical analyses have been proposed and are in current use,
including the Proportional Reporting Ratio (PRR)6, Reporting Odds Ratio (ROR)7, and Multi-Item Gamma Poisson
Shrinker (MGPS)8. The PRR and ROR are derived from report-level statistics with straightforward calculations, and
the MGPS is conceptually similar to the PRR with additional Bayesian shrinkage and stratification, which are useful
with limited data8. These traditional statistical methods are limited by their inability to draw relations between similar
drugs or between similar adverse events. This is analogous to a widely recognized problem with Natural Language
Processing (NLP) techniques based on discrete counts of words, which fail to recognize useful relationships between
them. There are two sorts of generalization that could improve performance of discrete count-based methods: (1)
generalization based on patterns of distribution (entities with similar distributions are similarly represented), as ex-
emplified by methods of distributional semantics such as skip-gram with negative sampling (SGNS - a component
of the popular word2vec package)9 and GloVe10; and (2) generalization based on structured knowledge available
in a lexicon. The second approach can be accomplished by combining methods of distributional semantics with
retrofitting, a method that uses structured knowledge to enhance distributionally-derived representations11. In
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the first case, the model learns to recognize patterns in the data, but doesn’t draw on knowledge beyond the training
corpus. In the second, the model should recognize both those relations implicit in the data and those explicitly defined
in a relevant knowledge resource.
In this paper, we first use a previously proposed algorithm, aer2vec12, which uses a similar architecture to SGNS
with variants that consider either drugs or ADEs as inputs at FAERS report level (rather than using a sliding window
based unit of context) to build distributed representations of drugs and ADEs. Unlike prior work with aer2vec12, we
apply the algorithm to FAERS data as is - without additional normalization and standardization. Next, we leverage the
retrofitting algorithm of Faraqui et al11 to combine distributional information of drugs with lexical information
from RxNorm, a U.S. National Library of Medicine project under the parent project of the Unified Medical Language
System (UMLS)13. Two key distinctions between our use of these methods and their original conception are that
we are using them to represent reporting data rather than language, and using the resulting vector representations to
recapitulate a probabilistically-motivated training objective (e.g. P (drug|ADE)) rather than comparing input weight
vectors directly (as is typical in word embedding applications). Our hypothesis is that retrofitting aer2vec vectors
will result in improvements in performance on pharmacovigilance signal detection tasks.
Methods
The underlying idea of our methods is to use aer2vec to train a set of drug embeddings, and then modify these
to conform with lexical information derived from RxNorm using a retrofitting algorithm that was originally
developed to enrich word embeddings with information from different lexical sources11. The training set for drug
and ADE embeddings is derived from FAERS. As with unmodified aer2vec representations, the probabilistically-
motivated training objective can be recapitulated to estimate P (drug|ADE). The resulting models are then evaluated
on two widely-used pharmacovigilance reference sets, one from the Observational Medical Outcomes Partnership
(OMOP)14, the other from the EU-ADR (Exploring and Understanding Adverse Drug Reactions) Project15.
FDA ADVERSE EVENT REPORTING SYSTEM DATA The FDA actively maintains the FAERS post-market surveil-
lance system. The system has been active since 1969, and experienced a major redesign in 1997, when the Medical
Dictionary for Regulatory Activities (MedDRA) was used to harmonize medical terminologies16. Both drugs and
ADEs in FAERS were mapped to this standardized dictionary. However, not all publicly available fields in the database
were mapped. For example, one important field for our study, DRUGNAME, was mapped to active ingredients (a field
named PROD AI) only after the third quarter of 2014. To test model performance using raw data with minimal pre-
processing and maximize data use, the DRUGNAME field was used in the current study. Since the source of FAERS
data is spontaneous reports, this field is not very well standardized. This required some minimal processing: (1) all
entries were changed into lower case; (2) spaces were replaced with underscores; (3) trailing special characters were
removed. ADEs have been mapped to canonical terms in a medical terminology (a MedDRA “Preferred Term”) since
the inception of the system, so this field was used directly in the study without any modification.
FAERS data include reporter designations of suspicion for drugs a patient was taking when an ADE was observed.
We used 13,636,783 publicly available records from 2004 to 2019, all but 134 of which have at least one designated
primary suspect (PS). There are other reported roles of drugs besides PS in the reports, such as SS (secondary suspect),
C (concomitant), and I (interacting). The main focus of the study is on both a set of all roles, and a set including
primary suspect drugs (PS) only. Restricting data to drugs designated with the PS identifier was shown to improve
model performance when evaluated using standard reference sets12. Consequently, we constructed two sets of report
data: FULL, which includes all report-level drug/ADE co-occurrence events, and PS which includes only those drugs
from a report that have been designated as primary suspects. These sets were used as training data for two independent
aer2vec models.
AER2VEC The aer2vec algorithm12 adapts the SGNS algorithm of Mikolov et al18, 19 to represent report-level
drug/ADE co-occurrence events. Retaining SGNS as a basic training framework, aer2vec introduces two neu-
ral architectures, aer2vec+ and aer2vec-, to predict P (drug|ADE) and P (ADE|drug) respectively. SGNS
is trained to predict the probability of observing each context term in a sliding window surrounding an observed
term, which is moved through a training corpus. In contrast, aer2vec models context at the report level where
co-occurrence events are observed, providing data for training of the relevant neural network architecture. As similar
representations will be learned for entities occurring in similar contexts, connections between similar drugs (such as
drugs resulting in the same ADEs) or similar ADEs (such as those resulting from the same drugs) can be inferred.
As aer2vec+ performed better on signal detection tasks12, we employed it for the current work. The FULL and PS
subsets of FAERS data were used to train ADE and drug embeddings using aer2vec+, as implemented in the open
source Semantic Vectorsi package20, 21, following the accompanying documentationii. In accordance with the
best-performing models described in the original work12, vectors of dimension of 100 for every drug (DRUGNAME)
and ADE (PT) were trained over ten iterations on each training set (without subsampling of frequently occurring en-
tities). The resulting embeddings provided initial information on drug and ADE distributions in the reports. Since
aer2vec training depends upon randomized order of presentation of the data and stochastic initialization of weight
vectors, we generated ten editions of each of the two embedding spaces, in order to assess robustness of performance.
RXNORM RELATIONS RxNorm is a project that started in 2001, with the goal of modeling clinical drugs and their
relationships under the Unified Medical Language System (UMLS)22. RxNorm provides extensive information on
clinical drugs, links across drug vocabularies, and drug interactions23. RxNorm is organized by concepts (denoted
as RxCUIs), adopting the structure used in the UMLS semantic network for a consistent categorization24. Each
concept then links to many related terms. For example, the concept of “rofecoxib” (RxCUI = 232158) is linked to
related terms where it is the ingredient, “rofecoxib” and “pridinol/rofecoxib”, and its pharmaceutical preparations
“rofecoxib 12.5 MG”, “rofecoxib 2.5 MG/ML” in the RxNorm database. For each concept (RxCUI), one or several
atoms (RxAUI) are categorized under it. For the same example of “rofecoxib”, it has atoms of “rofecoxib”, “4-[4-
(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone”, “3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone” (with
the latter two being chemical designations of the drug), amongst others. These terms could be used in mapping to
the DRUGNAME field of the FAERS dataset.
RxNorm is released on a monthly basis. For this study, the version released on January 6th, 2020 was used, including
6,574,327 relational records in total. Seven RxNorm relation types (RELs) are provided: RO, SY, RB, RN, SIB, CHD,
and PAR. In previous work evaluating the effect of retrofitting biomedical concept embeddings on the agreement be-
tween their pairwise similarities and human judgment, the combination of relationships RN (“narrower” relationship)
and RO (other relationship) improved performance25. In our study, SY (synonymy) was also included as a lexical re-
lationship with RN and RO, thus covering most instantiated RxNorm relations. Since RxNorm relations are organized
by RxCUIs, all associated atomic concepts were assumed to inherit relations from their parent RxCUI. The resulting
lexicon included 668,412 entries, with each RxCUI or RxAUI being an entry to retain the most granular information.
RETROFITTING retrofitting is a graph-based technique developed by Faruqui et al in order to integrate vector
space representations (word embeddings) with semantic lexicons11. The idea behind this method is to update the
target’s vector representation by bringing it closer to those of its lexical neighbors, thus integrating information from
them. This can be summarized in the following cost function to be minimized11:
Ψ(A) =
n∑
i=1
αi||qi − qˆi||2 + ∑
(i,j)∈E
βij ||qi − qj ||2
 (1)
whereE is the set of semantic relations of interest, qi the retrofitted representation for concept i (target), qˆi the original
vector representation for this concept, qj a neighbor of qi in E, and model parameters αi the weight for original vector
representations, and βij the weight for lexical information.
The method is able to retrofit vector representations generated by any algorithm. For the current work drug vectors
from aer2vec+ trained on the FULL and PS sets were used. The lexical information is from the RxNorm lexicons
described in the previous section covering relations RN, RO and SY. Retrofitting was accomplished using the
implementation provided by Faraqui and his colleaguesiii with minor modifications to avoid discarding terms with
certain characters. While Faruqui et al reported results with fixed hyperparameters after setting α = β = 0.5, we
experimented with adjusting their values to evaluate the effect on performance of balancing distributional information
ihttps://github.com/semanticvectors/semanticvectors
iihttps://github.com/treversec/aer2vec
iiihttps://github.com/mfaruqui/retrofitting
against lexical information. This was done by changing the value of β from 0 to 1 by increments of 0.1 while
maintaining α+ β = 1.
RESCALING In the original implementation of retrofitting, word vector representations are normalized before
proceeding. However, with aer2vec+, P (drug|ADE) is estimated as σ(−−−−→ADE ·−−−→drug) with−−−−→ADE and−−−→drug rep-
resenting the input and output weights of the neural network, respectively. This estimate is sensitive to the magnitude
of the weight vectors concerned, which is discarded upon normalization. To preserve this valuable information, a novel
rescaled version of retrofitting was developed, by using the lengths of the original aer2vec representations
to determine the lengths of their retrofitted counterparts:
vrri =
||vi||2
||vri||2 × vri (2)
where for word i, vrri is rescaled retrofitted vector representation, vri is retrofitted vector representation, vi is vector
representation from aer2vec. The euclidean norm is used for normalization. Similarly, these rescaled vectors were
evaluated under all pairs of α and β hyperparameter values.
BASELINE MODELS Disproportionality metrics, including the Proportional Reporting Ratio (PRR) and the Reporting
Odds Ratio (ROR), are widely-used pharmacovigilance methods to detect signals in spontaneous reporting system
data, such as in FAERS26 and the UK Yellow Card database27. Both PRR and ROR are derived from the 2 × 2 table
for a specific drug-ADE pair:
Table 1: Disproportionality Metrics
ADE of Interest Other ADEs
Drug of Interest a b
Other Drugs c d
Given Table 1 where a, b, c, d are all counts for co-occurrences, PRR and ROR can be expressed as:
PRR =
a
a+ b
/
c
c+ d
(3)
ROR =
a
b
/
c
d
(4)
The strengths of the PRR are its convenience to calculate, and that it is not affected by bias from varying reporting
frequencies
(
unlike methods such as reporting rates (# of reports divided by # of prescriptions)
)
, because the numerator
estimates the proportion of reports for a drug of interest that concern a particular ADE. However, one limitation of the
PRR is that a strong signal from a particular drug will reduce the magnitude of signals for other drug-ADE pairs6. The
ROR method makes predictions based on estimation of odds ratios, and this can be used to estimate relative risk if the
database is modified to simulate a case-control study by removing related drug-ADE pairs to create a “randomized”
control set7. However, from the formula, it is apparent that the ROR will not compute when any of b, c or d are
0. Practically, PRR and ROR are similar and give comparable results when used for signal detection, in terms of
sensitivity and specificity28. A common concern for these methods is that they treat drugs and ADEs as discrete
entities, and as such cannot generalize from data concerning related drugs (such as class effects) or ADEs (such as
organ system effects). It is these limitations that our methods aim to address.
EVALUATION SETS To evaluate model performance, two reference sets were used in the study, one from the Observa-
tional Medical Outcomes Partnership (referred to as the OMOP set), the other one from the EU-ADR (Exploring and
Understanding Adverse Drug Reactions) Project (referred to as the EU set). The OMOP set was developed through
systematic literature review and natural language processing of structured product labels to help establish classifica-
tions of positive and negative drug-ADE pairs14. To limit the scope of research, the group defined four main outcomes:
acute liver injury, acute kidney injury, acute myocardial infarction, and upper gastrointestinal bleeding. For the four
outcomes, 165 positive controls and 234 negative controls were identified. The EU set was built in a similar way by
Figure 1: Pipeline to generate embeddings from data subsets, with and without retrofitting.
integrating literature, drug product labels, and expert opinion, however unlike the OMOP set spontaneous report data
from the World Health Organization was also used, and they were key to generating the pool of negative controls
from which this aspect of the set was derived. Ten adverse events (bullous eruptions, acute renal failure, anaphylac-
tic shock, acute myocardial infarction, rhabdomyolysis, aplastic anaemia/pancytopenia, neutropenia/agranulocytosis,
cardiac valve fibrosis, acute liver injury, and upper gastrointestinal bleeding) were used as outcomes, and 94 drug-
ADE pairs accounting for 44 positive controls and 50 negative controls across these outcomes were then identified15.
For these two evaluation sets, performance was evaluated using the Area Under the Receiver Operating Character-
istic Curve (henceforth AUC). The five methods, aer2vec, aer2vec with retrofitting (with and without
rescaling), and two baseline models, were each applied to two separate data subsets: FULL and PS, and evaluated
using the two reference sets, OMOP and EU-ADR. With all aer2vec variants, P (drug|ADE) was estimated as
σ(
−−−−→
ADE · −−−→drug), and used to score the drug/ADE pairs in the sets. The entire workflow is illustrated in Figure 1.
Results
AER2VEC+ When training aer2vec+ on the FULL and PS sets, and evaluating on the EU and OMOP reference
sets, we obtain the AUC results shown in Table 2, which also includes baseline PRR and ROR results.
Table 2: aer2vec+ performance (AUC) vs PRR/ROR
OMOP EU
FULL PS FULL PS
aer2vec+ 0.72± 0.011 0.84± 0.005 0.80± 0.020 0.96± 0.005
PRR 0.64 0.73 0.83 0.89
ROR 0.64 0.73 0.83 0.89
When evaluating the method on the OMOP set (Table 2 left), aer2vec+ performs significantly better than the PRR
and ROR in both cases (PS and FULL). We find a similar pattern for the EU reference set (Table 2 right), with the
exception that the aer2vec+ algorithm performs slightly worse than the PRR or ROR statistics when trained on the
FULL set. The AUCs of aer2vec+ rise significantly from FULL to PS set in both evaluation sets, which is also
true for the baseline models of PRR and ROR. Both findings are consistent with previous work using a normalized
standardized set of FAERS data12. The overall performance of all three methods on the EU set is better than their
performance on the OMOP set. Moreover, with largest training set and smallest test set (FULL - EU), aer2vec+ has
the highest standard deviation of 0.02, as compared with that of 0.005 with the PS - OMOP set combination.
RETROFITTING OF DRUG EMBEDDINGS Results with retrofitting are shown in Figure 2 (left). Given equa-
tion (1), β (represented by the x axis) with value of 0 means there is no retrofitting involved, and all resulting vectors
are from the original aer2vec+ models (albeit with normalization when not rescaled). β with value of 1 means all
vectors come from fully retrofitted models, where the resulting vectors are updated without the constraint that they
should remain similar to their aer2vec-derived starting points, as determined by lexical information from RxNorm.
The AUCs of models trained on the PS set are always higher than those from the FULL set, whatever the value of
β is (p < 0.01, unpaired t-test). This is consistent with the findings described in the previous section where no
retrofitting was used at all, however we note that the normalization step of the retrofitting method re-
Figure 2: Effects of retrofitting on AUCs for FULL and PS set (10 iterations).
(a) retrofitting without rescaling on OMOP set (b) retrofitting with rescaling on OMOP set
(c) retrofitting without rescaling on EU set (d) retrofitting with rescaling on EU set.
sults in lower baseline (β = 0) performance with the OMOP set (p < 0.05, unpaired t-test), and a slightly higher
baseline performance with the EU set (p < 0.05, unpaired t-test).
When the retrofitting algorithm is applied (Figure 2 (a) (c)), the model performance increases as the weight
of retrofitting increases, but declines after a point with worst performance when lexical information is permitted to
predominate (β = 1). This is true for both FULL and PS sets when evaluated on both EU and OMOP reference sets.
However, the degree of improvement differs across these reference sets. With the OMOP set, aer2vec+ has a larger
increase in AUC when trained on the PS set. Conversely, when evaluated on the EU set the algorithm trained on the
FULL set benefits more. The difference from these evaluation sets also shows as the β values for algorithm to achieve
its best performance: in the EU set, it is β = 0.5 (FULL set) and β = 0.2 (PS set); in OMOP set, it is β = 0.5 (FULL
set) and β = 0.6 (PS set). These results show that information in lexicons can be utilized to improve aer2vec’s
performance in pharmacovigilance signal detection.
The rescaling results are shown in Figure 2 (right). When evaluated on the OMOP set ((a) and (b) in Figure 2), both
models (PS and FULL training sets) benefit from rescaling, with an overall gain in AUC of 0.05 on the FULL set and
0.04 on the PS set. Moreover, the retrofitting effect is more obvious when vectors are rescaled: when β increases, AUC
also increases and reaches its maximum when β = 0.5 for the FULL set. A similar pattern is also observed with the PS
set, but with a maximum AUC at a lower β (0.3), and the AUC dropping more quickly after the maximum point. After
Table 3: Retrofitting results (part) on the OMOP set with varying β. Best results in boldface with ROR and
aer2vec (β = 0.5) as points of comparison.
Without rescaling With rescaling
β FULL PS FULL PS
0 0.678± 0.010 0.809± 0.004 0.721± 0.011 0.844± 0.005
0.3 0.686± 0.010 0.822± 0.004 0.738± 0.009 0.858± 0.005
0.5 0.687± 0.009 0.826± 0.004 0.742± 0.008 0.846± 0.005
0.6 0.686± 0.009 0.826± 0.003 0.741± 0.007 0.834± 0.004
1.0 0.596± 0.007 0.775± 0.003 0.656± 0.005 0.705± 0.003
ROR 0.641 0.728 0.641 0.728
applying rescaling, the results on OMOP set are shown in Table 3. Since the results of PRR and ROR are very close,
only ROR is shown in tables. Compared with aer2vec without rescaling, we observe an overall increase in AUCs,
with different βs used to achieve maximal performance. These are the best results obtained with the aer2vecmethod
on the OMOP evaluation set in the current work. In contrast, when comparing (c) and (d) in Figure 2, performance on
the EU set does not benefit from rescaling, with slight decreases with both training sets. Furthermore, when evaluated
on this set, the normalized and rescaled vector representations have similar retrofitting effects, with slight increases
in AUC as the influence of retrofitting is initially increased. Table 4 shows partial EU set results. Rescaled
retrofitting performs best at β = 0.1, but retrofitting without rescaling performs best overall.
Table 4: Retrofitting results (part) on the EU set with varying β. Best results in boldface with ROR and
aer2vec (β = 0.5) as points of comparison.
Without rescaling With rescaling
β FULL PS FULL PS
0 0.822± 0.019 0.969± 0.005 0.802± 0.020 0.964± 0.005
0.1 0.826± 0.019 0.971± 0.005 0.803± 0.023 0.964± 0.005
0.2 0.831± 0.018 0.972± 0.004 0.801± 0.022 0.963± 0.004
0.5 0.840± 0.018 0.959± 0.006 0.794± 0.017 0.946± 0.009
1.0 0.719± 0.011 0.834± 0.006 0.699± 0.011 0.809± 0.007
ROR 0.828 0.889 0.828 0.889
Discussion
In this paper, we evaluated the utility of combining two methods, aer2vec and retrofitting. We hypothesized
that this combination would improve pharmacovigilance performance with aer2vec when trained on a minimally
preprocessed FAERS dataset, without normalization or standardization. The aer2vec method was developed to
model empirical ADE reports for pharmacovigilance signal detection, and showed its utility when trained on stan-
dardized FAERS data12. Its application to minimally preprocessed FAERS data has not been evaluated previously.
The retrofitting method was originally used to refine semantic vector space representations of words11, and its
application to retrofit data-derived concept embeddings for the purpose of predictive modeling is a novel aspect of the
current work, as is the rescaling modification of this method to preserve information encoded by vector magnitude.
Evaluations on both EU and OMOP sets show improvements with retrofitting over aer2vec as the retrofitting
effect (β) increases, but the optimal β differs from set to set, as does the influence of rescaling. On the larger and
more challenging OMOP set, the combination of these two methods (retrofitting with rescaling) produces an
improvement over baseline models, the PRR and ROR. On the EU set, retrofitting alone leads to best perfor-
mance, comfortably outperforming these disproportionality metrics, which are in current use for pharmacovigilance
signal detection. This illustrates their capability as a means of mining spontaneous ADE reports, and highlights the
potential utility of combining empirically-derived embeddings with lexical information. Lexical information from
RxNorm serves as a complement to distributional information learned from the data directly, which in our case in-
cludes data from spontaneous reports but excludes drug classes, relations, and hierarchy, just as most distributional
semantics algorithms don’t take lexical knowledge beyond their training corpus into account.
The results also illustrate the feasibility and stability of aer2vec when trained on a minimally preprocessed FAERS
dataset, without standardization or normalization. The aer2vec+ model trained on raw data performs relatively
well. Portanova et al reported best AUCs of 0.86 and 0.96 on the EU set when training on the FULL and PS sets
respectively, and 0.76 and 0.88 on the OMOP set when training on the FULL set and the PS set12. The performance of
the same algorithm trained on the raw FAERS dataset (shown where β = 0 with rescaling in Table 3 and Table 4) was
not better than that on the standardized set. However, combining aer2vec and retrofitting (with and without
rescaling) achieved the best results on these two reference sets in the current experiments, surpassing results with the
standardized set in one instance. Our models achieved best AUCs of 0.84 (std = 0.018) and 0.97 (std = 0.004)
on the EU set ( retrofitting without rescaling) when trained on the FULL and PS sets respectively, and 0.74
(std = 0.008) and 0.86 (std = 0.005) on the OMOP set (retrofitting with rescaling) when trained on the
FULL and PS sets respectively, which suggests that retrofitting can to some degree compensate for the lack of
standardization and normalization with raw FAERS data. However, these results are not strictly comparable because
Portanova et al’s model was trained using data from up to the 2015 release only. The availability of more current
data than that which is available in standardized form shows one advantage of utilizing minimally preprocessed data
where little effort is required for harmonizing and mapping of terms. Another advantage is that the computational
work required to perform this mapping would need to be repeated for the entire data set if any change in relational
structure occurred, whereas the retrofitting procedure can be readily and rapidly (around three minutes for our
dataset) applied to aer2vec representations that are generated without reference to predefined lexical knowledge.
As with previous research12, information in FAERS reports about PS designations proved to be very useful in improv-
ing model performance in all scenarios, including the aer2vec model, retrofitting algorithm, and even the
PRR and ROR. One reason this field improves performance is that it designates reporters’ suspicion and the reporters
may have access to temporal information and background knowledge that is not explicit in the reports themselves.
While there will likely be bias when expert opinion is involved, in this scenario, the trade-off appears warranted, to the
extent our reference standards are reliable indicators of system accuracy after deployment. The effect of rescaling on
retrofitting differs on two reference sets. As discussed above, rescaling increases AUCs by approximately 0.05
when evaluated on the OMOP set, but it has a negative effect with the EU evaluation set (a decrease about 0.02-0.03).
Our working hypothesis is that the information encoded by magnitude is obscured in the case of the EU-FULL set,
because the drugs in this set are far more frequently reported (median=18,457 vs. 2,395 for the OMOP set), and neural
embeddings of words that occur in a broad variety of contexts tend to have shorter vectors due to representations of
some of their surroundings canceling each other out29.
One concern about the current evaluation is that our training data (to 2019) extends past the point of publication of
our evaluation sets (in 2013), which may mean that information that arose subsequently to the judgments in these sets
was utilized. To assess whether or not this affected performance we re-ran our experiments using data from up to
2013 only, with α fixed at 0.5. Relative performance of the methods was similar, with greatest improvements observed
with retrofitting with rescaling in the context of the FULL set. Surprisingly, some experiments (e.g. with FULL
models on the EU set) revealed better performance with this restricted data set, which suggests that in the absence
of provider designation constraints these models may be disadvantaged by increases in false positive signals. We
also evaluated performance across the four side effects in the OMOP set, and noted that performance benefits from
the original retrofitting procedure were found in acute myocardial infarction and acute hepatic failure only. However
with rescaling, performance for all four OMOP outcomes benefits from retrofitting. This explains the some of the
improvement in in overall performance, although further research is required to determine why some side effects
benefit more from this procedure than others.
Limitations
While we have shown that performance measured against a widely-used reference set improves more with retrofitting,
it is not yet fully apparent how this improvement is realized. While it seems self-evident that the retrofitted vectors
incorporate information from drugs that are related in RxNorm and that this might be beneficial, in future work we
plan to compare similarities between drug or ADE vectors of the same class before and after retrofitting. This
becomes important when minimally preprocessed data are used. The DRUGNAME field contains exactly what was
reported from a variety of sources without standardization. Synonyms or different spellings of a drug may disperse
signal for drugs, which may fail to reach their generic names,as used in both the OMOP and EU evaluation sets.
Future work will therefore involve closely monitoring how key drugs and their relatives are repositioned in vector
space during the course of the retrofitting process. Also, only three relations (RO, RN, and SY) were used to build the
lexicon. The explicit expansion of deeper relations (such as second-order ones) was also not implemented. Though
one would anticipate the iterative nature of the retrofitting procedure capturing some of this information implicitly,
it remains possible that encoding the nature of these relationships explicitly would lead to further improvements in
performance. An additional limitation is that the balance between distributional and lexical information is controlled
by two hyper parameters (α and β) whose optimal values may depend on the original vectors, lexicons, and reference
set. Furthermore, the two reference sets, EU and OMOP, were used for all evaluations. As with previous work12
model performance on the OMOP set is generally lower than that on the EU set. One potential explanation for
this concerns how the EU set is constructed, especially its negative controls. According to the EU-ADR project15,
Bayesian disproportionality analysis of the WHO spontaneous reporting database was used to create the pool for
negative controls. This database is similar in nature to the FAERS, from which our training data were collected. In
contrast, the OMOP project used product labeling, systematic literature review, and literature search to select negative
control candidates14. Lastly, these sets have been criticized for over-representation of well-established side-effects30.
This concern could be addressed by using time-delimited data, and reference examples from recently-added label
warnings31.
Conclusion
We evaluated the applicability of the aer2vec algorithm to minimally preprocessed FAERS data, and the util-
ity of retrofitting, which augments aer2vec distributional representations with additional lexical informa-
tion. aer2vec outperforms disproportionality metrics in most configurations, and the original implementation of
retrofitting together with aer2vec further improves performance. Furthermore, our novel rescaled variant
of the retrofitting algorithm results in significantly better performance on the larger (OMOP) reference set. The im-
provements in performance on a minimally preprocessed dataset make retrofitting a good alternative to explicit
standardization, with potential application to a broad range of observational data sources.
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